Nephropathies rank among the top global causes of chronic organ failure and mortality. Youngen's KIDNI SHUTTLE™ delivery platform delivers therapeutics to renal tubular epithelial cells with potent efficacy and an excellent safety profile. Precision nephrology targets root disease-driving genetic aberrations within kidney tissue.

For more information about immune mediated therapy and iga nephropathy treatment, please feel free to contact us!

Youngen has been dedicated to bringing RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general, impacting millions of people and families around the world. Leveraging cutting-edge technological platforms, we build globally competitive diversified product pipelines with first-in-class and best-in-class potentials. We're exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders.

If you are looking for a reliable biopharmaceutical research company, please contact us.

Cardiomyopathies and heart failure are prevalent life-threatening cardiac conditions caused by impaired myocardial function, serving as key therapeutic targets for cardiac-targeted siRNA delivery. Youngen is exploring RNAi-based approaches for cardiovascular diseases treatment by addressing underlying disease-causing mechanisms. Youngen's KARDIA SHUTTLE™ delivery platform delivers drugs to cardiomyocytes with a high potency and superior safety profile, supporting the development of targeted cardiovascular therapy. Precision cardiology targets an underlying disease-causing genetic mutation in the cardiac muscle and provides a potential direction for more precise metabolic disorders treatment. Youngen also applies its RNAi research capabilities to metabolic treatment, focusing on molecular pathways associated with metabolic dysfunction. These efforts support the development of new metabolic disorders treatment strategies for diseases with significant unmet medical needs. Together, targeted delivery and precision medicine approaches may expand the potential of cardiovascular pharmacotherapy while maintaining a focus on efficacy and safety.

For more information about cardiovascular disease solutions and cardiovascular pharmacotherapy, please feel free to contact us!

For the details of rna interference and cardiovascular treatment, please visit our website!

Advantages of Technology Platform

Youngen has developed a Fast Integrated Screening Technology called FlSTsiran that is uniquely positioned to rapidly identify RNA molecules with potent activity, long durability and superior safety.

Youngen has developed a Multi-targeted Single-entity Technology called MSTsiran  that is capable of incorporating two or more different siRNAs. This technology could be applied to treat many complex diseases that are caused by the dysregulation of more than one gene or multiple diseases.

Youngen has developed a siRNA Transport Technology called STTsiran that can significantly enhance the activity of siRNA drugs in extra-hepatic tissues. This technology enables tissue-specific targeting, including the brain for central nervous system treatment, as well as muscle and adipose.

For more information about us technological innovation and new innovation of science, please feel free to contact us!

Youngen has been dedicated to bringing RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general, impacting millions of people and families around the world. Leveraging cutting-edge technological platforms, we build globally competitive diversified product pipelines with first-in-class and best-in-class potentials. We're exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders.

If you are looking for a reliable biopharmaceutical company, please contact us.

Leveraging mature hepatic targeting strategies and optimized oligonucleotide modification systems, Youngen’s liver-targeted delivery pipelines enable efficient, stable, and high-specificity accumulation of RNAi therapeutics in hepatocytes with a favorable safety profile. Differentiated from conventional single-target therapies, our metabolic pipelines adopt a dual-target therapeutic strategy, simultaneously intervening in core pathogenic genes and key metabolic signaling pathways that drive lipid overaccumulation, glucose metabolic disorder. We aim to provide novel and potent RNAi therapeutic solutions for refractory obesity and chronic metabolic diseases. Beyond cardiovascular and metabolic programs, Youngen is also advancing research in cns neuroscience and therapeutics, exploring RNAi-based approaches for cns therapy and other neurological applications. Our research efforts in cns therapy focus on developing innovative strategies that address disease-related molecular targets and expand the potential of RNAi therapeutics. Through continued research, Youngen aims to support the development of new cns treatment, central nervous system treatment, and cns disease treatment approaches for patients with difficult-to-treat neurological disorders.

For more information about central nervous system treatment and medication for nervous system disorders, please feel free to contact us!

If you are looking for a reliable biotechnology company, please contact us.

There are many biopharmaceutical companies, but we are one of the best choices for you.

Cardiac Diseases

Cardiomyopathies and heart failure are prevalent life-threatening cardiac conditions caused by impaired myocardial function, serving as key therapeutic targets for cardiac-targeted siRNA delivery. Youngen is exploring RNAi-based approaches to develop a targeted therapeutic solution for these serious cardiac conditions.

Cardiovascular and Metabolic Diseases

Leveraging mature hepatic targeting strategies and optimized oligonucleotide modification systems, Youngen’s liver-targeted delivery pipeline enables efficient, stable, and high-specificity accumulation of RNAi therapeutics. These platform capabilities support the development of advanced biotech solutions and innovative therapeutic solutions for cardiovascular and metabolic diseases.

Renal Disorders

Hair loss is a type of skin disease, and the common types of hair loss are mainly divided into androgenic alopecia, alopecia areata, psychogenic alopecia, genetic alopecia, etc. 95% of the hair loss belongs to androgenic alopecia. Youngen continues to expand its research capabilities through advanced biotechnical solutions across multiple therapeutic areas.

CNS Disorders

Hair loss is a type of skin disease, and the common types of hair loss are mainly divided into androgenic alopecia, alopecia areata, psychogenic alopecia, genetic alopecia, etc. 95% of the hair loss belongs to androgenic alopecia. Through continued scientific innovation, Youngen aims to advance life therapeutic solutions for diseases with significant unmet medical needs.

If you are looking for a reliable therapeutic solutions inc, please contact us.

For more information about innovative therapeutic solutions and biotech solutions, please feel free to contact us!

As a trustworthy and reliable biotech company, youngenbiomed trys our best to provide good products and service for you.

There are many biomedical companies, but we are one of the best choices for you.